focus -WSS

focus

author：focus 2025-10-01 11:43:49 - browse：5482

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

“The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： As AI regulations shape up, health tech startups beg for clarity

explore

WSS

Emergency medicine has repudiated 'excited delirium.' Now what?

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Why Sanofi got shellacked over its spinoff

Senate panel to vote on hospitals, PBMs, prisoner care

Medicare Advantage enrollment hits roughly 33.4 million

Weight loss drugs aren’t covered by Obamacare. That may change

entertainment

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Virginia high school admissions case could be legal follow

Chimpanzees, like humans and whales, get menopause: Study

Heart attack and stroke risk calculators need revising

New study raises questions about niacin and heart health

Malaria cases in Florida and Texas: Here’s what you need to know

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Moonlake's readout produced a cash windfall. Risks remain

WATCH: Why do our ears pop?

Sports medicine is finally prioritizing gender equality

Flagship Pioneering startup Sonata Therapeutics lays off 21

explore

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Readout Newsletter: XBI biotech index, Akero Therapeutics

Opioid cravings were reduced by anti

Opioid cravings were reduced by anti

Traditional Chinese medicine benefits explored in new JAMA study

Ukraine seeks to reclaim its role as a hub for clinical trials

focus

focus

explore

focus